Following the government’s various announcements, the Alsatian laboratory Toda Pharma is mobilizing to meet the surge in demand. With the construction of an additional temporary building and the hiring of numerous temporary workers, the laboratory expects to triple its production by January.
Tripled production, adapted to individual needs
Based in Strasbourg, the French laboratory Toda Pharma has been offering, since 2020, in addition to serological and antigen tests, a COVID-19 Nasal Self-Test, which, according to a comparative study by the Paul Ehrlich National Center and six national institutes commissioned by the German Ministry of Health, presents: Excellent performance across the 122 main tests on the European market, including a reliability rate of over 86% and a sensitivity rate of 99%.
Subject to strict quality control and the subject of several feasibility studies guaranteeing clinical performance at the same level as antigen tests, it can also be used on children from 6 years old.
In recent weeks, with the explosion of COVID-19 cases and government announcements, we have had to anticipate new orders. We have therefore adapted our production capacities to avoid possible shortages while maintaining the quality of our products, which will prove crucial in the coming weeks to fight the pandemic. We have also optimized the ergonomics of our products to make them as easy to use as possible and thus offer the same level of reliability for individuals as when used by a healthcare professional.
Thibaut Mandicourt, Toda Pharma Quality Manager.
